From Research at med.fsu.edu Fri Jul 2 09:15:19 2021 From: Research at med.fsu.edu (med-Research) Date: Fri, 2 Jul 2021 13:15:19 +0000 Subject: Important information re: TMH IRB fees In-Reply-To: References: Message-ID: Good morning, COM research community! Please see the following message from the FSU Office for Clinical Research Advancement (OCRA) regarding TMH collaborations and IRB fees. Questions can be directed to OCRA (OCRA at fsu.edu). Please note that OCRA should be engaged early in your protocol and proposal budget development process. Feel free to direct any proposal related questions to Med-RA (research at med.fsu.edu). Thank you, College of Medicine Office of Research Administration (Med-RA) Important information for faculty conducting human subjects research: Tallahassee Memorial HealthCare (TMH) recently updated its IRB review fee schedule to incorporate a 30% discount for FSU researchers collaborating with TMH. The discount will be applied to the listed fees, which can be found at https://ocra.fsu.edu/clinical-collaborators/ Any FSU researcher planning to collaborate with TMH should work with the Office for Clinical Research Advancement (OCRA) to address what TMH IRB fees outlined in the schedule may apply to the study and, if the study is unfunded, how to request consideration for a fee reduction or waiver. Although the TMH IRB has had a fee structure in place for years, the discount was just implemented in June in recognition of the collaborative partnership between FSU and TMH. For that, we are very appreciative! As you may be aware, IRB fees are a standard practice among healthcare research institutions like hospitals as a way to recoup a small portion of their costs to support operations such as IRB reviews. Universities typically recoup similar overhead expenses by budgeting into grant applications indirect costs that come back to the university as part of the grant award. Because TMH does not have a federally negotiated rate for recouping overhead costs if their clinician researchers apply for extramural grant awards, assessing IRB fees is how TMH can recoup a portion of its research operational costs. As with any study-related costs, FSU researchers who plan a collaboration with institutions like TMH should include in grant proposals any fees from external IRBs. Likewise, studies being funded by researcher start-up funds or other internal university awards that allow such costs to be budgeted also should include external costs like IRB fees. Going forward, for funded studies that anticipate collaborating with external institutions such as TMH, researchers should contact OCRA at fsu.edu before finalizing the protocol and budget. TMH will need to review those study materials in order to provide a letter of support and ensure that resources are budgeted for the collaboration. Thank you for working with us on this aspect of our research collaboration with TMH, and continued best wishes for your research endeavors. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Wed Jul 14 07:44:10 2021 From: Research at med.fsu.edu (med-Research) Date: Wed, 14 Jul 2021 11:44:10 +0000 Subject: Weekly Funding Opportunities Message-ID: Medline Community Impact Grant Program Throughout our nation we are faced with many health inequities. Health outcomes for people living in vulnerable communities, and already disproportionately impacted by social determinants of health (SDOH), are at an even greater health risk. SDOH are the economic and social conditions that influence individual and group differences in health status. Medline is committed to social determinants of health and through the Community Impact Grant Program we can promote good health for all people.? ? Medline is investing resources to help non-profit organizations address prevalent health challenges, stimulate health equity and improve population health in under resourced areas. We will award results-focused grants that offer community- centered solutions and immediate impact. Through collaboration with community experts, we can provide essential resources, re-direct adverse outcomes and improve the well-being of people. This is, and always will be, our ongoing commitment to communities. $25,000 awards. Due August 27, 2021. Med-RA deadline to receive draft documents: August 16. Program on the Origins of Gastroesophageal Cancers (R01 Clinical Trial Optional) The National Cancer Institute (NCI) is publishing this Funding Opportunity Announcement (FOA) to request applications for the Program on the Origins of Gastroesophageal Cancers (R01). This new program will build on recent molecular classifications of gastroesophageal cancers, significant understanding of their cancer genomics, and advances in stem cell research to examine and define how these related cancers initially evolve at the cellular level. The program will address the complex mechanisms and effectors that direct the proliferation and expansion of tumor-initiating cells and their progeny to initiate these cancers. The focus of the FOA is on gastric and gastroesophageal junction adenocarcinomas. The program is envisioned to provide unprecedented opportunities to outline the earliest cellular changes in transformation that precede any histological manifestations or neoplasia. This new program will be composed of up to six large R01 research grants (to be supported by this FOA) and one Coordinating Center grant (to be supported by the companion FOA, RFA-CA-21-027). Due October 8, 2021. Med-RA deadline to receive draft documents: September 27. CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to support research seeking to understand mechanisms of chemical toxicity and to identify potential molecular/genetic targets that reduce acute effects of chemical threat agents that affect the lungs and eyes. These discoveries can lead to exploration of therapeutic countermeasures through early stage development efforts supported by the Countermeasures Against Chemical Threats (CounterACT) NIH-wide program, a component within the Chemical Countermeasures Research Program (CCRP). Due October 13, 2021; September 21, 2022; and September 20, 2023. Med-RA deadline to receive draft documents for October 13, 2021 due date: September 30. Innovative Models for Delivering PrEP and STI Services to Stop HIV in the United States (R61 / R33 Clinical Trial Optional) The purpose of this FOA is to encourage and support the development of effective strategies for expanding the provision of HIV pre-exposure prophylaxis for people at increased risk but currently lacking these services by leveraging existing sexually transmitted infection programs. Funding for the fourth and fifth years(s) will be dependent upon achieving negotiated Go/No-go criteria and milestones. Due October 13, 2021. Med-RA deadline to receive draft documents: September 30. HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R61 Clinical Trial Not Allowed) The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R61 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research ? for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed).Thus, the limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R61 awards will support the building of a research team to collect initial data and recruit additional collaborators. The application must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease. Due October 13, 2021; June 9, 2022; October 11, 2022; June 9, 2023; October 10, 2023. Med-RA deadline to receive draft documents for October 13, 2021 due date: September 30. Exploratory Studies to Investigate the Mechanisms of Interrelationship between Sleep and Substance Use Disorders (R61/R33) R61/R33 Basic Experimental Studies with Humans Required The purpose of this FOA is to support research project applications that are developmental and exploratory in nature to expand our knowledge on the basic neurobiology of the interrelationship between sleep and substance use disorders (SUDs). Projects may explore the molecular, cellular, circuit and behavioral interactions between sleep and SUDs. R61/R33 Clinical Trials Not Allowed The purpose of this FOA is to support research project applications that are developmental and exploratory in nature to expand our knowledge on the basic neurobiology of the interrelationship between sleep and substance use disorders (SUDs). These mechanistic studies will not only offer an insight into the fundamental processes that link substance use disorders to disorders of sleep regulation and vice-versa but may also have implications for managing the risk for the development of SUDs and identifying new targets for prevention and therapeutics. Due October 14, 2021. Med-RA deadline to receive draft documents: October 4. Exploratory Studies to Investigate the Mechanisms of Interrelationship Between Sleep and Substance Use Disorders (R61/R33) Clinical Trials Not Allowed Basic Experimental Studies with Humans Required The purpose of this FOA is to support research project applications that are developmental and exploratory in nature to expand our knowledge on the basic neurobiology of the interrelationship between sleep and substance use disorders (SUDs). These mechanistic studies will not only offer an insight into the fundamental processes that link substance use disorders to disorders of sleep regulation and vice-versa but may also have implications for managing the risk for the development of SUDs and identifying new targets for prevention and therapeutics. Projects may explore the molecular, cellular, circuit and behavioral interactions between sleep and SUDs. Due October 14, 2021. Med-RA deadline to receive draft documents: October 4. Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) is to support applications to a new NIAMS initiative to encourage the skin research community to contribute to basic understanding of skin injuries caused by chemical threats to the civilian population, with an emphasis on investigating the commonalities of such injuries and identifying potential shared signaling pathways and therapeutic targets for countermeasure development. Standard dates apply. Expires September 8, 2024. Med-RA deadline to receive draft documents for October 16, 2021 standard date: October 5. NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01- Clinical Trial Optional) This Funding Opportunity Announcement (FOA) is intended to provide an avenue for basic scientists, clinicians and clinical scientists to jointly initiate and conduct translational research projects which translate basic research findings into clinical tools for better human health. The scope of this FOA includes a range of activities to encourage translation of basic research findings which will impact the diagnosis, treatment and prevention of communication disorders. Connection to the clinical condition must be clearly established and the outcomes of the grant must have practical clinical impact. Due October 20, 2021; June 20, 2022; February 22, 2023; October 18, 2023; June 20, 2024. Med-RA deadline to receive draft documents for October 20, 2021 due date: October 7. Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 / R01 Clinical Trial Required) R34 The goal of this funding opportunity is to support early phase clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) for conditions that have been identified by NCCIH as high priority research topics. This funding opportunity is intended to support feasibility clinical trials, which will provide data that are critical for the planning and design of a subsequent clinical efficacy or effectiveness study, or a pragmatic trial. The data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: examining feasibility and acceptability of interventions lacking published data; adapting an intervention to a specific population; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention and data collection procedures; refining and assessing the feasibility of protocolized multimodal interventions; or examining acceptability and adherence of control conditions. This FOA will not support randomized clinical trials that test or determine efficacy or effectiveness; nor will this FOA support repetition of feasibility or acceptability research that has been previously conducted in the same or similar patient population with the same or similar intervention. Applications that propose solely to write a protocol or manual of operations or to develop infrastructure for a clinical trial are not appropriate for this announcement. Applications must propose to conduct a feasibility clinical trial. The subsequent larger trial should have the potential to make a significant impact on public health. R01 This Funding Opportunity Announcement (FOA) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. Applications submitted under this FOA are expected to propose a multi-site feasibility clinical trial to assess whether the intervention can be delivered with fidelity across sites; demonstrate feasibility of recruitment, accrual, and randomization of participants across sites; demonstrate participant adherence to the intervention, as well as retention of participants throughout the study across sites; and/or demonstrate feasibility of data collection across sites in preparation for a future fully powered, multi-site efficacy/ effectiveness trial. The need for multi-site feasibility trials is expected to be justified by sufficient preliminary data from previous single site feasibility or acceptability trial(s) or the published literature. This FOA will not support clinical trials that determine efficacy or effectiveness. The data collected should be used to fill gaps in scientific knowledge and be necessary to develop a competitive fully powered multi-site clinical trial that has the potential to make a significant impact on public health Due October 20, 2021; February 18, 2022; June 20, 2022; October 19, 2022; February 21, 2023; June 20, 2023; October 20, 2023; February 20, 2024. Med-RA deadline to receive draft documents for October 20, 2021 due date: October 7. Promoting Bunyavirales Basic Science Research (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to stimulate fundamental research of human disease-causing pathogens in the Bunyavirales order by supporting projects studying vector competence, virology, pathogenesis, and immunity. Due October 22, 2021. Med-RA deadline to receive draft documents: October 11. High Resolution Mapping of Biomolecules in Brain Cells in Aging and Alzheimer?s Disease (R01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) will use the R01 funding mechanism to support discrete, specified, and circumscribed projects on novel molecular imaging approaches to establish high-resolution mapping of biomolecules in brain cells and regions during the course of aging and Alzheimer?s disease (AD). Due October 28, 2021. Med-RA deadline to receive draft documents: October 18. Leveraging Existing Large Databases and Cohorts to Better Understand the Risks and Benefits of Long-Term Osteoporosis Therapy and Drug Holiday (R01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) solicits secondary analyses of existing datasets to provide evidence about appropriate strategies for long-term osteoporosis therapies, including drug holidays, and to better understand their risks and benefits. This FOA encourages interdisciplinary studies utilizing innovative analytical approaches such as modeling studies or causal inference methods using data sources from large cohort studies, healthcare systems including the Veterans Administration (VA), Centers for Medicare and Medicaid Services (CMS), FDA Sentinel network, Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention (CDC), and other public, private, or commercial datasets. The generalizability of study results is critical, and datasets should be representative of the population receiving osteoporosis therapy. Identification of disparities in outcomes according to demographic, ethnic, clinical, social, and other factors are particularly encouraged. Due October 28, 2021. Med-RA deadline to receive draft documents: October 18. Role of Adaptive Immunity in Etiology of Alzheimer?s Disease and Alzheimer?s Disease-Related Dementias (R01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) aims to explore the role of adaptive immunity in Alzheimer?s disease and Alzheimer?s disease-related dementias (AD/ADRD). Specifically, the FOA seeks an understanding of brain immune surveillance, the generation of CNS-directed immune responses in neurodegenerative disorders, and the functional role of adaptive immunity in AD/ADRD onset and progression. Due October 28, 2021. Med-RA deadline to receive draft documents: October 18. BRAIN Initiative: Optimization of Transformative Technologies for Large Scale Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed) Understanding the dynamic activity of neural circuits is central to the NIH BRAIN Initiative. The invention, proof-of-concept investigation, and optimization of new technologies through iterative feedback from end users are key components of the BRAIN Initiative. This FOA seeks applications to optimize existing or emerging technologies through iterative testing with end users. The technologies and approaches should have potential to address major challenges associated with recording and modulation (including various modalities for stimulation/activation, inhibition and manipulation) of cells (i.e., neuronal and non-neuronal) and networks to enable transformative understanding of dynamic signaling in the central nervous system (CNS). These technologies and approaches should have previously demonstrated their transformative potential through initial proof-of-concept testing and are now ready for accelerated refinement. In conjunction, the manufacturing techniques should be scalable towards sustainable, broad dissemination and user-friendly incorporation into regular neuroscience research. Proposed technologies should be compatible with experiments in behaving animals, validated under in vivo experimental conditions, and capable of reducing major barriers to conducting neurobiological experiments and making new discoveries about the CNS. Technologies may engage diverse types of signaling beyond neuronal electrical activity such as optical, electrical, magnetic, acoustic or genetic recording/manipulation. Applications that seek to integrate multiple approaches are encouraged. If suitable, applications are expected to integrate appropriate domains of expertise, including biological, chemical and physical sciences, engineering, computational modeling and statistical analysis. Due October 29, 2021; May 2, 2022; October 28, 2022; May 1, 2023; October 27, 2023. Med-RA deadline to receive draft documents for October 29, 2021 due date: October 18. BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed) Understanding the dynamic activity of brain circuits is central to the NIH BRAIN Initiative. This FOA seeks applications for proof-of-concept testing and development of new technologies and novel approaches for recording and modulation (including various modalities for stimulation/activation, inhibition and manipulation) of cells (i.e., neuronal and non-neuronal) and networks to enable transformative understanding of dynamic signaling in the central nervous system (CNS). This FOA seeks exceptionally creative approaches to address major challenges associated with recording and modulating CNS activity, at or near cellular resolution, at multiple spatial and/or temporal scales, in any region and throughout the entire depth of the brain. It is expected that the proposed research may be high-risk, but if successful, could profoundly change the course of neuroscience research. Proposed technologies should be compatible with experiments in behaving animals, validated under in vivo experimental conditions, and capable of reducing major barriers to conducting neurobiological experiments and making new discoveries about the CNS. Technologies may engage diverse types of signaling beyond neuronal electrical activity such as optical, magnetic, acoustic and/or genetic recording/manipulation. Applications that seek to integrate multiple approaches are encouraged. If suitable, applications are expected to integrate appropriate domains of expertise, including biological, chemical and physical sciences, engineering, computational modeling and statistical analysis. Due October 29, 2021; May 2, 2022; October 28, 2022; May 1, 2023; October 27, 2023. Med-RA deadline to receive draft documents for October 29, 2021 due date: October 18. Prevention of Perinatal Depression: Improving Intervention Delivery for At-Risk Individuals (R34 / R01 Clinical Trial Required) R34 R01 The purpose of these Funding Opportunity Announcements (FOAs) is to encourage research addressing major gaps identified in the United States Preventive Services Task Force recommendation statement concerning interventions to prevent perinatal depression, with an emphasis on populations experiencing mental health disparities. The research scope for these FOAs includes: 1) refining and pilot testing strategies for identifying women at risk for perinatal depression; 2) developing and testing tools for selecting those most likely to benefit from preventive interventions; 3) refining and testing service-ready efficacious preventive interventions that are of appropriate intensity/dose, and are scalable, such that they can be delivered with fidelity by setting providers; and, 4) optimizing and testing strategies that can be used to train providers and to support delivery of evidence-based approaches with fidelity across diverse health care and community settings. Due November 9, 2021. Med-RA deadline to receive draft documents: October 27. PrEP for HIV Prevention among Substance Using Populations (R01 ? Clinical Trial Optional) NIDA is interested in research that addresses research gaps related to PrEP and its use among people who use drugs (PWUD), with the goals of improving PrEP uptake, adherence and implementation. Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. More systematic data are needed regarding the impact of substance use on PrEP management and adherence, as well as the best ways to deliver PrEP and integrate it with other services. Recent trials have demonstrated the efficacy of injectable Cabotegravir as PrEP, although no data exist for PWUD and there is a need to inform the best practices for delivery and management of injectable PrEP among PWUD, as well as for oral PrEP. This RFA is restricted to projects conducted in the United States. Applications are encouraged that propose research in states and counties identified in the US Government?s Ending the HIV Epidemic (EHE) initiative. Applications to work in locales that are not included in the EHE initiative must provide an epidemiologic justification for their inclusion in the research. Due November 12, 2021. Med-RA deadline to receive draft documents: November 1. Organoid Modeling of Neural Stimulants and HIV Comorbidity of Human Brain (R01- Clinical Trial Optional) This Funding Opportunity Announcement (FOA) invites grant applications to study mechanisms underlying the neuropathophysiology of HIV-associated neurological disorders (HAND) using induced microglia and cerebral organoids generated from human derived induced pluripotent stem cell (iPSC) lines. Specific emphasis is on the comorbidity of HIV and neural stimulants, including methamphetamine, amphetamine, cocaine, and nicotine, studied at the single cell and neural circuits levels. Due November 17, 2021. Med-RA deadline to receive draft documents: November 3. Understanding Oral Human Papillomavirus (HPV) Infection, Acquisition, and Persistence in People Living with HIV (R21 / R01 Clinical Trial Not Allowed) R21 R01 The purpose of these Funding Opportunity Announcements is to solicit research to better understand the epidemiology and biology of oral human papillomavirus (HPV) infection, its acquisition and persistence, in people living with HIV and elucidate the initial mechanisms related to HPV-associated oral and oropharyngeal cancers and warts in the context of HIV. The FOAs intend to address broad knowledge gaps related to biological, immunogenetic, clinical, and socio-behavioral factors and mechanisms for oral HPV co-infection and persistence in the oral cavity and oropharynx of HIV-seropositive individuals. Due November 18, 2021. Med-RA deadline to receive draft documents: November 4. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Mon Jul 19 15:56:13 2021 From: Research at med.fsu.edu (med-Research) Date: Mon, 19 Jul 2021 19:56:13 +0000 Subject: Weekly Funding Opportunities Message-ID: Dear Colleague Letter: UKRI/BBSRC - NSF/BIO Lead Agency Opportunity in Biological informatics, Microbes and the Host Immune System, Quantum Biology, and Synthetic Cell Through this Dear Colleague Letter (DCL), the NSF Directorate for Biological Sciences (NSF/BIO) and the UKRI Biotechnology and Biological Sciences Research Council (BBSRC) are pleased to announce 2021/2022 topical areas associated with this lead agency opportunity. The lead agency opportunity allows for reciprocal acceptance of peer review through unsolicited mechanisms; its goal is to help reduce some of the current barriers to working internationally. Topics of interest: Biological Informatics Proposals are invited that address the development of novel informatics approaches and cyberinfrastructure resources to enable novel and effective use of data in biological research, addressing key challenges faced by researchers and supporting generation of new knowledge from biological data. Proposals must be aligned to BOTH NSF's Division of Biological Infrastructure programs in informatics and cyberinfrastructure AND UKRI/BBSRC's Data Driven Biology Responsive Mode priority. In addition, Principal Investigators (PIs) are advised to consult the appropriate program officer to ensure that their portion of the project is compliant with the targeted program. Microbes and the Host Immune System Proposals are invited that take an integrated approach to answer important questions relating to the immune system and host-microbe interactions. Microbes impact their hosts in manners that result in greatly different outcomes, which can include symbiotic, mutualistic or pathogenic infection. Key to these outcomes is the response and resilience of the host innate and adaptive immune system, as well as the microbial players (bacterial, fungal, viral) and the underlying physiological context. Relevant areas of investigation include systems using genetically-similar hosts or microbes that result in different phenotypic outcomes of infection. The use of comparative cross-species approaches to develop insights that have broad relevance across biological organisms is encouraged, as is research to understand the influence of co-infection and the wider microbiome and the influence of host physiology through the life course. Proposals should aim to identify molecular mechanisms or develop systems-level understanding. Proposals that focus on industrial applications will not be accepted. Proposals that focus solely on human or mouse immune systems will not be accepted. Proposals must aim to progress knowledge of immunology in non-human animals or plants. Quantum Biology Proposals are invited that seek to investigate the biological molecules and biomolecular systems that give rise to quantum mechanical effects in living organisms. Studies have shown that such phenomena are important to a number of fundamental biological processes, including photosynthesis, olfaction, cellular respiration, and vision, yet the specialized features that enable such effects are not well understood. Relevant areas of investigation include the features of proteins that enable quantum effects to occur at physiological temperatures and the significance of the relatively large size of most protein complexes that exhibit quantum phenomena in contributing to the superposition of quantum states that give rise to quantum entanglement or quantum coherence. Mechanistic insight into the extended coherence times observed in biological systems is also of interest. In addition to biophysical mechanisms, proposals that aim to provide insights into the prevalence of quantum phenomena in biological systems across the tree of life and their evolutionary origins are also welcome. Proposals must aim to progress biological understanding and are expected to integrate research and methodologies from both (bio)physics and biology. Synthetic Cell Can we design, build and control a synthetic cell? Realizing this grand challenge will enable us to uncover the molecular and physical organization of cells that enable storage and transmittal of information, capture and transformation of energy, and adaptation and regulation of cellular systems that make life possible. Natural cells emerge from the coordinated operation of a large number of biomolecules with their environment. One goal of synthetic cell research is to decipher the basic requirements of a living cell by understanding the myriad functions that make it resilient and adaptive. To this end, proposals are expected to focus on building a synthetic cell in order to understand biology. For example, the identification of genes, metabolic pathways and cellular components and the molecular mechanism by which they exert their function can inform and accelerate the design and building of synthetic cells. Such cells might be protocells containing only the most basic cellular components that allows an understanding of the origin of life, artificial cells that contain both natural and synthetic cellular components or minimal cells that use natural molecules to build self-replicating cellular entities through 'bottom up' approaches. Proposals focused exclusively on building a synthetic cell as a biomanufacturing platform or as a therapeutic moiety will not be accepted. 2-page intention to submit due September 22, 2021. Med-RA deadline to receive draft documents: September 9. Technology Development for Single-Molecule Protein Sequencing and Single-Cell Proteome Analysis (R21 / R01 Clinical Trial not allowed) R21 This Funding Opportunity Announcement (FOA) solicits R21 grant applications to catalyze major advances in single-molecule protein sequencing through technology development. The goal of this initiative is to achieve technological advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed, cost and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA. R01 This Funding Opportunity Announcement (FOA) solicits grant applications to catalyze major advances in single-molecule protein sequencing and single cell proteome analysis through technology development. The goal of this initiative is to achieve technological advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed, cost and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general. Due October 1, 2021; June 15, 2022; June 15, 2023. Med-RA deadline to receive draft documents: September 20. Large Research Projects for Prevention of Healthcare-Associated Infections (R01) This FOA issued by AHRQ invites grant applications for funding to conduct Large Research Projects (R01) that propose to advance the base of knowledge for detection, prevention, and reduction of Healthcare-Associated Infections (HAIs). This FOA describes the broad areas of HAI research for which funds are available to support Large Research Projects. Standard dates apply. Expires May 27, 2025. Med-RA deadline to receive draft documents for October 5, 2021 standard date: September 22. Pediatric Immune System ? Ontogeny and Development (INTEND) (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to correlate immune system development patterns between two or more age groups ? neonates, infants, and children and adolescents and further understand the impact of infectious diseases, microbiome and environmental factors on the ontogeny and development of the pediatric immune system, from birth, transitioning into adolescence and adulthood with the focus of impact during pregnancy and post-natal period. Due October 5, 2021; February 5, 2022; October 5, 2022; February 5, 2023; October 5, 2023; February 5, 2024. Med-RA deadline to receive draft documents for October 5, 2021 due date: September 22. Metabolic Dysregulation and Cancer Risk Program, Research Grants: a Transdisciplinary Approach to Obesity-Associated Research (U01 Clinical Trial Optional) The National Cancer Institute (NCI) invites research grant applications for transdisciplinary studies that will enhance our knowledge of the dynamics and underlying mechanisms that link obesity, metabolic dysregulation and increased cancer risk as part of the Metabolic Dysregulation and Cancer Risk Program. Through this Funding Opportunity Announcement (FOA), the Metabolic Dysregulation and Cancer Risk Program will focus on metabolic dysregulation as the key process linking obesity with cancer risk. For the purpose of this FOA, metabolic dysregulation is defined as alterations in glucose utilization and storage, insulin sensitivity, and/or lipid metabolism. Applications should specifically seek to advance our understanding of how metabolic dysregulation in individuals affects cancer risk and identify mechanisms that will enhance (i) cancer risk prediction, (ii) screening for high-risk individuals in clinical settings, and (iii) identification of potential targets for preventive and therapeutic interventions. Due October 6, 2021. Med-RA deadline to receive draft documents: September 23. Cancer Target Discovery and Development (CTD2) (U01 Clinical Trial Not Allowed) Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support the program ?Cancer Target Discovery and Development? (CTD2, pronounced cee-tee-dee-squared). CTD2 is focused on efforts that advance cancer research by bridging the knowledge gap between the large volumes of comprehensive molecular characterizations of many cancer types and studies of the underlying etiology of cancer development, progression, and/or metastasis. The primary purpose of CTD2 is to advance the following areas: * Improving the understanding of how mutations in cancer-associated genes affect the protein activity (e.g., gain-of-function, loss-of-function, or neomorphic function) within the cellular pathway(s) they are part of and the cellular changes that result within the context of various tumors and the microenvironment; * Identifying new molecular targets with the goal to understand their wiring mechanisms and how to overcome innate and/or acquired resistance to therapies, particularly clinical resistance related to inter- and intra- tumor heterogeneity; and * Developing efficient strategies to identify appropriate multiple targets and optimal combination of perturbagens (chemical or biological; immunotherapeutics being a prime example of the latter) with the potential to eliminate all cancer cells, despite their clonal heterogeneity and their surrounding microenvironment. This FOA solicits applications for U01 cooperative agreement research projects addressing the areas outlined above. The proposed projects should use a combination of state-of-the-art high throughput informatic and experimental approaches to: characterize and validate novel cancer targets; develop precise perturbagens that can affect the proposed targets of cancer treatments and define the mechanism(s) of action; identify molecular markers that can meaningfully predict responses or resistance to anticancer therapies and develop algorithms that can be applied to predict responses to treatments and/or define more precise treatment modalities. Due October 6, 2021; February 8, 2022; October 6, 2022. Med-RA deadline to receive draft documents for October 6, 2021 due date: September 23. R01: BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science Guided by the goals established in BRAIN 2025: A Scientific Vision and reinforced by the Advisory Council to the Director Working Group on BRAIN 2.0 Neuroethics Subgroup, this Funding Opportunity Announcement (FOA) from the NIH Brain Research through Advancing Innovative Neurotechnologies? (BRAIN) Initiative is intended to support efforts addressing core ethical issues associated with research focused on the human brain and resulting from emerging technologies and advancements supported by the BRAIN Initiative. This FOA encourages research project grant applications from multi-disciplinary teams focused on key ethical issues associated with BRAIN Initiative supported research areas. Efforts supported under this FOA are intended to be both complementary and integrative with the transformative, breakthrough neuroscience discoveries supported through the BRAIN Initiative. Due October 13, 2021; October 11, 2022; October 11, 2023. Med-RA deadline to receive draft documents for October 13, 2021 due date: September 30. HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 / R01 Clinical Trial Not Allowed) R21 R01 The purpose of these Funding Opportunity Announcements (FOAs) is to support research projects focusing on the identification of druggable new targets and discovery of optimizable probes for development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. These FOAs are part of the NIH Helping to End Addictions Long-term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose. Due October 19, 2021. Med-RA deadline to receive draft documents: October 6. Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions (R01 Clinical Trial Not Allowed) The purpose of the Funding Opportunity Announcement is to invite applications to identify and characterize microbial metabolites that will establish causal associations between microbial metabolism and host health and disease. Data acquired through this initiative will be used to create a knowledge base of microbial metabolites and associated functions that will be provided to the research community. Due October 20, 2021; June 22, 2022; October 20, 2022; June 22, 2023; October 19, 2023. Med-RA deadline to receive draft documents for October 20, 2021 due date: October 7. Aging Research in Animals (ARIA): Promoting Rigorous Research on Behavioral and Social Processes (R61 / R33 Clinical Trial Not Allowed) The overarching objective of this funding opportunity announcement (FOA) is to develop and strengthen animal models for behavioral and social research in the interest of furthering the mechanistic understanding of how social and physical environmental factors contribute to aging processes and the etiology and progression of age-related conditions and diseases. With the explicit two-fold goal of identifying socio-environmental sources of aging processes and advancing the integration of behavioral, social, and environmental measures into biological hallmarks of aging, this FOA invites R61/R33 phased innovation applications that propose to develop and test behavioral and social methods, tools, and measures in: (1) research on the natural history of aging in populations of wild animals to increase the understanding of the complex interplay of social and environmental factors which affect individual differences in aging trajectories and health outcomes; and (2) basic and applied research in captive animals that can improve the validity and value of animal models for basic and translational research. Funded projects will receive up to two years of R61 support for initial developmental, proof-of-concept activities, and up to three years of R33 research to support implementation. Projects may involve primary or secondary analysis of data collected in animals from well-characterized wild populations, captive populations, or both. Due October 20, 2021. Med-RA deadline to receive draft documents: October 7. Primary Care-Based Screening and Intervention Development for Prevention of Abuse in Older and Vulnerable Adults in the Context of Alzheimer?s Disease and Related Dementias (R61 / R33 Clinical Trial Required) The purpose of this funding opportunity announcement (FOA) is to support research that can lead to the development of evidence-based primary care screening tools and behavioral interventions to prevent abuse in at-risk older and vulnerable adults with mild cognitive impairment (MCI) and Alzheimer?s disease and Alzheimer?s disease-related dementias (AD/ADRD) and their families. Specifically, this FOA invites R61/R33 applications proposing Stage I screening and behavioral intervention development and Stage III efficacy trials in primary care settings. Studies must directly address the priority research needs and gaps highlighted in the U.S. Preventive Services Task Force?s 2018 final recommendation statement on Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults: Screening for the development and validation of the following: 1. Reliable and accurate screening instruments or assessments in primary care settings for older and vulnerable adults without recognized signs or symptoms of abuse (i.e., asymptomatic), and for their medical visit companions, at the time of diagnosis of MCI or AD/ADRD and subsequent primary care encounters; and/or 2. Brief and effective point-of-care psychoeducational and behavioral interventions for the prevention of all types of abuse. Due October 20, 2021. Med-RA deadline to receive draft documents: October 7. Computational Approaches for Validating Dimensional Constructs of Relevance to Psychopathology (R01 Clinical Trial Optional) / Computationally-Defined Behaviors in Psychiatry (R21 Clinical Trial Optional) Computational Approaches for Validating Dimensional Constructs of Relevance to Psychopathology (R01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) solicits applications for research projects that will use computational approaches to test the validity of dimensional constructs in the NIMH Research Domain Criteria (RDoC) matrix (or similar constructs based on comparable criteria). Some elements of the RDoC matrix have been updated since its first release, but a thorough data-driven validation that broadly explores, compares, and validates the constructs within the matrix has not been performed. This FOA seeks research that addresses the following questions: Do the different domains of behavior segregate from each other? How much do they rely on distinct versus overlapping neural circuits? What are the relationships between domains, constructs, and subordinate sub-constructs, both in terms of their correlational structure and their underlying neural circuitry? By answering these questions, proposed research projects will test integrative models of functioning and identify dysregulation in psychopathology-related mechanisms that may cut across traditional diagnostic categories and may change over time. This FOA seeks to promote projects where the computational and the experimental components are well integrated. To ensure ecological validity of these studies, models derived from lab-based behavioral tasks will need to be tested for generalizability to behavioral data collected in a real-world setting. The ultimate goal is to advance translational research that will identify novel classification approaches and/or treatment targets, and lead to more effective and timely interventions for serious mental illnesses. Computationally-Defined Behaviors in Psychiatry (R21 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) solicits applications for research projects that will apply computational approaches to develop parametrically detailed behavioral assays across mental-health relevant domains of function. These projects should focus on behavior in humans and test computational models in healthy, trans-diagnostic, unselected, or community samples. NIMH is particularly interested in the study of behavioral measures, models, and parameters that have the potential for back-translation from humans to animals, especially for pre-clinical therapeutics development, and in models that have the potential to be extended to clinical populations. To maximize prospects of back-translation and to provide a neurobiological foundation for future research, studies will need to consider behavioral models and parameters that are linked to the underlying neural processes that may be involved in their computation. Finally, in order to ensure ecological validity of behavioral assays, models derived from lab-based behavioral tasks will need to be tested for generalizability to behavioral data collected in a real-world setting. Due November 1, 2021; November 1, 2022; November 1, 2023. Med-RA deadline to receive draft documents for November 1, 2021 due date: October 19. Elucidating the Roles of Transposable Elements in AD/ADRD and Aging (R01 Clinical Trial Not Allowed) The goal of this Funding Opportunity Announcement (FOA) is to support hypothesis-driven research to gain an understanding of the dysregulation of transposable elements (TE) and their contributions to Alzheimer?s disease (AD) and Alzheimer?s disease-related dementias (ADRD) and aging. This FOA encourages applications that investigate causal effects of TE activation in disease and aging and applications that model therapeutic interventions to facilitate the transition of the field from observational discovery towards a deeper mechanistic understanding of the function and regulation of TEs. Due November 2, 2021. Med-RA deadline to receive draft documents: October 20. Growing Great Ideas: Research Education Course in Product Development and Entrepreneurship for Life Science Researchers (UE5 Clinical Trial Not Allowed) * Courses for Skills Development * Curriculum or Methods Development This FOA seeks applications to develop a customized curriculum and implement education programs/short courses in biomedical entrepreneurship, innovation and biomedical product development, specifically targeting scientists working in the field of drug addiction research. The institution proposing the course must be an institution that has an established and well-recognized entrepreneurship teaching program with the demonstrated ability and passion to adapt/develop and deliver an integrated curriculum for academic life scientists. Due November 18, 2021. Med-RA deadline to receive draft documents: November 4 (due to Veterans Day holiday). Innate Immune Memory Impacting HIV Acquisition and/or Control (R21 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement is to investigate innate immune cell effector functions and innate immune memory as a means to prevent HIV infection and/or establishment of disease. Exploratory research from basic molecular mechanisms, translational work, and clinical research examining innate memory are encouraged. Due December 6, 2021. Med-RA deadline to receive draft documents: November 22 (due to Thanksgiving holiday). Elucidating the Effects of ART on Neuronal Function in the Context of SUD and HIV (R01 ? Clinical Trials Not Allowed) The National Institute on Drug Abuse [NIDA] seeks research applications to identify the effects of anti-retroviral therapy (ART) used for the treatment of HIV/AIDS on neuronal and glial structure and function, particularly when occurring in a background of chronic exposure to addictive substances including opioids, cocaine and other stimulants, cannabinoids, and nicotine. The overall goal of this funding opportunity is to determine the contributions of ART in the neurological and neurocognitive deficits that are linked to HIV-Associated Neurocognitive Disorders [HAND] in people living with HIV (PLWH) and substance use disorders (SUD). Due February 2, 2022. Med-RA deadline to receive draft documents: January 20. Dyadic Interpersonal Processes and Biopsychosocial Outcomes (R01s) R01 Clinical Trials Not Allowed This funding opportunity announcement (FOA) invites basic and/or methodological research projects that seek to illuminate or measure independent and interdependent health-related effects within dyads. For the purpose of this FOA, a dyad is a unit of two individuals whose interactions and influences on one another are nested within larger social contexts and networks. Both animal and human subjects research projects are welcome. Types of projects submitted under this FOA include but are not limited to, observational studies involving humans, or existing/synthesized datasets studies. Researchers proposing basic science experimental studies involving human participants (i.e., experimentally manipulate independent variables) should consider the companion FOA PAR-21-280? Dyadic Interpersonal Processes and Biopsychosocial Outcomes (R01 Basic Experimental Studies with Humans).? Due February 5, 2022 and February 5, 2023. Med-RA deadline to receive draft documents for February 5, 2022 due date: January 25. R01 Basic Experimental Studies with Humans This funding opportunity announcement (FOA) invites basic and/or methodological research projects that illuminate and/or measure independent and interdependent health-related effects within dyads across relationships and settings. For the purpose of this FOA, a dyad is a unit of two individuals whose interactions and influences on one another are nested within larger social contexts and networks. Dyads are social relationships that extend beyond the individual and have strong bidirectional influences on physical and mental health. For the purpose of this FOA, independent effects are those effects that affect each member of the dyad individually (i.e., by nature of being part of the dyad), whereas interdependent effects are those that affect one member of the dyad contingent upon the other member of the dyad (i.e., not only because the individual is part of a dyad but also because being part of the dyad has an effect on the other individual within the dyad as well). Due March 5, 2022 and March 5, 2023. Med-RA deadline to receive draft documents for March 5, 2022 due date: February 22. New Investigators to Promote Workforce Diversity in Genomics, Bioinformatics, or Bioengineering and Biomedical Imaging Research (R01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Human Genome Research Institute (NHGRI), National Institute of Biomedical Imaging and Bioengineering (NIBIB), and All of Us Research Program (All of Us). This program is intended to support Early Stage Investigators and New Investigators from groups underrepresented in the health-related sciences. Due February 22, 2022 and February 22, 2023. Med-RA deadline to receive draft documents for February 22, 2022 due date: February 9. NIDA Animal Genomics Program (U01 ? Clinical Trial Not Allowed) The purpose of the NIDA Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie: 1. Phenotypes associated with addictive behaviors and/or vulnerability to distinct stages along the substance use disorder (SUD) trajectory (e.g. initial/acute use, escalation of use, acquisition of tolerance, dependence, uncontrolled use, abstinence and relapse or recovery); 2. Behaviors associated with SUD (e.g. impulsivity, novelty seeking, delayed discounting, and other genetically-associated phenotypes); and 3. Comorbidities that demonstrate genetic correlations with phenotypes and behaviors linked with SUD (e.g. anxiety, stress, poor maternal care, social defeat, and other paradigms). Applications may examine any type of variant, including single nucleotide variants (SNVs), indels, large and small structural variants, and all types of mobile DNA. NIDA encourages applications that take genomics, multi-omics, and/or data-based approaches that integrate multi-level ?omics data, delineate gene networks, and/or uncover the function of known or newly discovered genetic or epigenetic variants. NIDA expects these studies to uncover novel mechanisms that contribute to SUD and facilitate the discovery of targets for intervention and guide the development of individualized therapeutics to treat these different aspects of SUD. Due March 2, 2022; July 26, 2022; March 2, 2023; July 26, 2023; March 4, 2024. Med-RA deadline to receive draft documents for March 2, 2022 due date: February 17. Biophtonics The Biophotonics program is part of the Engineering Biology and Health cluster, which also includes: 1) the Biosensing program; 2) the Cellular and Biochemical Engineering program; 3) the Disability and Rehabilitation Engineering program; and 4) the Engineering of Biomedical Systems program. The goal of the Biophotonics program is to explore the research frontiers in photonics principles, engineering and technology that are relevant for critical problems in fields of medicine, biology and biotechnology. Fundamental engineering research and innovation in photonics is required to lay the foundations for new technologies beyond those that are mature and ready for application in medical diagnostics and therapies. Advances are needed in nanophotonics, optogenetics, contrast and targeting agents, ultra-thin probes, wide field imaging, and rapid biomarker screening. Low cost and minimally invasive medical diagnostics and therapies are key motivating application goals. Research topics in this program include: * Imaging in the second near infrared window: Research that advances medical applications of biophotonics in the second near-infrared window (NIR-II: 1,000-1,700 nm) in which biological tissues are transparent up to several centimeters in depth, making this spectral window ideal for deep tissue imaging. * Macromolecule markers: Innovative methods for labeling of macromolecules. Novel compositions of matter. Methods of fabrication of multicolor probes that could be used for marking and detection of specific pathological cells. Pushing the envelope of optical sensing to the limits of detection, resolution, and identification. * Low coherence sensing at the nanoscale: Low coherence enhanced backscattering (LEBS). N-dimensional elastic light scattering. Angle-resolved low coherence interferometry for early cancer detection (dysplasia). * Neurophotonics: Studies of photon activation of neurons at the interface of nanomaterials attached to cells. Development and application of biocompatible photonic tools such as parallel interfaces and interconnects for communicating and control of neural networks. * Microphotonics and nanophotonics: Development and application of novel nanoparticle fluorescent quantum-dots. Sensitive, multiplexed, high-throughput characterization of macromolecular properties of cells. Nanomaterials and nanodevices for biomedicine. * Optogenetics: Novel research in employing light-activated channels and enzymes for manipulation of neural activity with temporal precision. Utilizing nanophotonics, nanofibers, and genetic techniques for mapping and studying in real-time physiological processes in organs such as the brain and heart. Proposals accepted anytime. Med-RA deadline to receive draft documents: Ten business days before submission to sponsor. Nanoscale Interactions The Nanoscale Interactions program is part of the Environmental Engineering and Sustainability cluster, which also includes: 1) the Environmental Engineering program; and 2) the Environmental Sustainability program. The goal of the Nanoscale Interactions program is to support research to advance fundamental and quantitative understanding of the interactions of nanomaterials and nanosystems with biological and environmental media. Materials of interest include one- to three-dimensional nanostructures, heterogeneous nano-bio hybrid assemblies, dendritic and micelle structures, quantum dots, and other nanoparticles. Such nanomaterials and systems frequently exhibit novel physical, chemical, photonic, electronic, and biological behavior as compared to the bulk scale. Collaborative and interdisciplinary proposals are encouraged. Research areas supported by the program include: * Characterization of interactions at the interfaces of nanomaterials and nanosystems, including both simple nanoparticles and complex and/or heterogeneous composites and nanosystems, with surrounding biological and environmental media; * Development of predictive tools based on the fundamental behavior of nanostructures to advance cost-effective and environmentally benign processing and engineering solutions over full-life material cycles; * Examination of the transport, interaction, and impact of nanostructured materials and nanosystems on biological systems and the environment; * Simulations of nanoparticle behavior at interfaces, in conjunction with experimental comparisons, and new theories and simulation approaches for determining the transport and transformation of nanoparticles in various media; and * Investigations of quantum vibronic and spin phenomena with correlations to nano phenomena. The Nanoscale Interactions program will support exploratory research projects on nanoscale interactions of quantum effects which explain macroscopic changes and physiological and metabolic processes; investigate quantum vibration and electron spin to elucidate nano phenomena and produce quantitative data and evidence of quantum effects. Research in these areas will enable the design of nanostructured materials and heterogeneous nanosystems with desired chemical, electronic, photonic, biological, and mechanical properties for optimal and sustainable handling, manufacture, and utilization. Proposals accepted anytime. Med-RA deadline to receive draft documents: Ten business days before submission to sponsor. Fluid Dynamics The Fluid Dynamics program is part of the Transport Phenomena cluster, which also includes 1) the Combustion and Fire Systems program; 2) the Particulate and Multiphase Processes program; and 3) the Thermal Transport Processes program. The Fluid Dynamics program supports fundamental research toward gaining an understanding of the physics of various fluid dynamics phenomena. Proposed research should contribute to basic scientific understanding via experiments, theoretical developments, and computational discovery. Major areas of interest and activity in the program include: * Turbulence and transition: High Reynolds number experiments; large eddy simulation; direct numerical simulation; transition to turbulence; 3-D boundary layers; separated flows; multi-phase turbulent flows; flow control and drag reduction. A new area of emphasis is high speed boundary layer transition and turbulence; the focus would be for flows at Mach numbers greater than 5 to understand cross-mode interactions leading to boundary layer transition and the ensuing developing and fully developed turbulent boundary layer flows. Combined experiments and simulations are encouraged. * Bio-fluid physics: Bio-inspired flows; biological flows with emphasis on flow physics. * Non-Newtonian fluid mechanics: Viscoelastic flows; solutions of macro-molecules. * Microfluidics and nanofluidics: Micro-and nano-scale flow physics. * Wind and ocean energy harvesting: Focused on fundamental fluid dynamics associated with renewal energy. * Fluid-structure interactions: NSF interests are in general FSI applications across the low- to high-Reynolds number range. In addition an NSF-AFOSR (Air Force Office of Scientific Research) joint funding area is the theory, modeling and/or experiments for hypersonic applications. Proposals will be jointly reviewed by NSF and AFOSR using the NSF merit review process. Actual funding format and agency split for an award (depending on availability of funds) will be determined after the proposal selection process. The AFOSR program that participates in this initiative is the Aerothermodynamics program (program officer: Dr. Sarah Popkin). * Canonical configurations: Experimental research is encouraged to develop spatiotemporally resolved databases for canonical configurations to either confirm historical results or to provide data in an unexplored parameter region. Fidelity and completeness for theoretical/computational validation are key attributes of the proposed experimental data. * Artificial intelligence (AI)/machine learning: Innovative AI ideas related to the use of machine learning and other AI approaches in fluid dynamics research to model and control the flows are encouraged. Verifying new models with canonical configurations, when appropriate, is encouraged for the Computational and Data-Enabled Science & Engineering (CDS&E) program. * Instrumentation and Flow Diagnostics: Instrument development for time-space resolved measurements; shear stress sensors; novel flow imaging; and velocimetry. Proposals accepted anytime. Med-RA deadline to receive draft documents: Ten business days before submission to sponsor. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Wed Jul 21 13:33:32 2021 From: Research at med.fsu.edu (med-Research) Date: Wed, 21 Jul 2021 17:33:32 +0000 Subject: FDOH Funding Opportunities Message-ID: The Florida Department of Health (FDOH) has released four research funding opportunity announcements. PLEASE NOTIFY COM Med-RA (research at med.fsu.edu) IF YOU INTEND TO RESPOND (OR PARTICIPATE IN A COLLABORATIVE RESPONSE) TO ANY OF THESE ANNOUNCEMENTS. Please note that three of these programs (*) limit the number of applications submitted by FSU. Additional internal paperwork and approvals may be required to submit your Letter of Intent. Letters of Intent are required for all programs and must be reviewed by COM Med-RA three business days prior to submittal. * Ed and Ethel Moore Alzheimer's Disease Research Program*: Letter of Intent due August 6, 2021 by 5:00 EST. Deadline for Med-RA review: August 3, 2021. * William G. "Bill" Bankhead, Jr., and David Coley Cancer Research Program*: Letter of Intent due August 11, 2021 by 5:00 EST. Deadline for Med-RA review: August 6, 2021. * James and Esther King Biomedical Research Program*: Letter of Intent due August 11, 2021 by 5:00 EST. Deadline for Med-RA review: August 6, 2021. * Live Like Bella Pediatric Cancer Research Initiative: Letter of Intent due August 20, 2021 by 5:00 EST. Deadline for Med-RA review: August 17, 2021. FDOH is offering two on-line informational sessions for these funding opportunities: An Informational Webinar on Microsoft Teams will be conducted on July 23, 2021 and July 28,2021 from 9:00 AM - 10:30 AM EST to allow for questions and answers in real time. Please join from your computer, tablet or smartphone: 9:00 AM July 23, 2021 FY21-22 FOA Overview and Q&A 9:00 AM July 28, 2021 FY 21-22 FOA Overview and Q&A Feel free to direct any questions to Med-RA at research at med.fsu.edu. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Thu Jul 29 12:26:17 2021 From: Research at med.fsu.edu (med-Research) Date: Thu, 29 Jul 2021 16:26:17 +0000 Subject: Weekly Funding Opportunities Message-ID: American Gastroenterological Association: Digestive Disease Health Disparities Research Grants of up to $30,000 will be awarded to recipients at any career stage establishing new research projects in digestive disease health and healthcare disparities. Projects must be related to understanding the causes of such disparities or testing interventions intended to eliminate them. They may focus on the pathophysiology, epidemiology, prevention, diagnosis, patient access to or quality of care, treatment, or patient outcomes of digestive diseases or disorders associated with a health difference closely linked with economic, social, or environmental disadvantages. Applicants performing any type of research (basic, translational, clinical) relevant to digestive disorders are eligible to apply. Through the program, there are numerous awards available: * AGA Pilot Research Award in Health Disparities: Open to investigations of disparities associated with any digestive disease or disorder. A total of two awards are available. * AGA-Amgen Pilot Research Award in Health Disparities: Open to investigations of disparities associated with any digestive disease or disorder. One award is available. * AGA-Bristol Myers Squibb Pilot Research Award in Inflammatory Bowel Disease Health Disparities: Open to investigations of disparities in inflammatory bowel disease. One award is available. * AGA-Merck Pilot Research Award in Colorectal Cancer Health Disparities: Open to investigations of disparities in colorectal cancer. One award is available. * AGA-Pfizer Pilot Research Award in Inflammatory Bowel Disease Health Disparities: Open to investigations of disparities in inflammatory bowel disease. One award is available. Due August 26, 2021. Med-RA deadline to receive draft documents: August 18. American Gastroenterological Association-Medtronic Pilot Research Award in Artificial Intelligence This award provides $30,000 for one year to independent investigators at any career stage to support research on artificial intelligence for applications in gastroenterology, hepatology, pancreatology and/or endoscopy. The objective of this AGA Research Foundation Pilot Research Award is to provide funds to early career investigators to help establish their research careers or to support projects that represent new research directions for established investigators. Projects must be clinically relevant and focus on the development, implementation, or evaluation of artificial intelligence (AI) for applications in gastroenterology, hepatology, pancreatology and/or endoscopy. Proposals addressing health economics or quality improvement will also be considered. Due August 26, 2021. Med-RA deadline to receive draft documents: August 18. Concern Foundation: Conquer Cancer Now Award The Concern Foundation helps to bridge the gap that currently exists in the scientific research community by supporting promising early career scientists and providing critically-needed ?seed? money for innovative research projects. To advance this mission, the foundation is inviting Letters of Intent for its Conquer Cancer Now Award program. Through the program, grants of $60,000 a year for up to two years will be awarded to researchers in support of innovative research in the areas of cancer genetics, cancer biology, or cancer immunology. The foundation does not fund clinical trials, cancer epidemiology, or behavioral studies. To be eligible, applicants must be an independent investigator at the start of his/her scientific career (i.e., junior faculty) and at the level of assistant professor (or equivalent, with explanation). PIs must have been in their current position for at least one year at the time of submission of the LOI. Letter of intent due September 8, 2021. Note: Pre-eligibility questionnaire closes September 6. Med-RA deadline to receive draft documents: August 25 (due to Labor Day holiday). Congressionally Directed Medical Research Programs Combat Readiness Medical Research Program Rapid Development and Translational Research Award Pre-application (preproposal): August 31, 2021. Invited full application: December 1, 2021. Med-RA deadline to receive draft documents for preproposal due date: August 18. Focus areas include sleep disorders and would care solutions. Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to invite research grant applications (R01) for the development and use of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo. The motivation for this initiative is that much of current imaging research into the role of inflammation in cancer is largely based on in vitro and ex vivo methods with limited utilization of imaging approaches that could lead to significant new insights relevant to dynamic cancer and inflammation interactions. Utilization of molecular imaging probes in pre-clinical and clinical investigations for precise temporal resolution at the molecular and cellular level are valuable approaches for identification and characterization of in vivo inflammatory cellular physiology in cancers and of molecular changes in response to treatment. This FOA encourages applications that focus on developing integrated imaging approaches to interrogate the role of inflammation in cancer through strong cross-field collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance science and understanding of cancer inflammation interactions. Standard dates apply. Expires September 8, 2024. Med-RA deadline to receive draft documents for October 5, 2021 standard date: September 22. Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 / R01 Clinical Trial Optional) R21 R01 The purpose of these Funding Opportunity Announcements (FOAs) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. These FOAs aim to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new therapies is outside the scope of these FOAs, though development of novel tools/methods to enable relevant mental health studies is encouraged. Standard dates apply. Expires September 8, 2024. Med-RA deadline to receive draft documents for October 5, 2021 standard date: September 22. NCI Research Specialist Awards: Core-based Scientist and Laboratory-based Scientist (R50 Clinical Trial Not Allowed) These Funding Opportunity Announcements (FOAs) invite grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. R50 Core-based Scientist The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity. R50 Laboratory-based Scientist The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These non-tenure track scientists, such as researchers within a research program, are vital to sustaining the biomedical research enterprise. It is anticipated that only exceptional scientists who want to pursue research within the context of an existing NCI-funded cancer research program, but not serve as independent investigators, will be competitive for this award. Due November 1, 2021. Med-RA deadline to receive draft documents: October 19. BRAIN Initiative Cell Atlas Network (BICAN): Specialized Collaboratory on Human, Non-human Primate, and Mouse Brain Cell Atlases (U01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) intends to support a group of Specialized Collaboratories that will adopt scalable technology platforms and streamlined sampling strategies and assay cascade to create comprehensive and highly granular brain cell atlases in human, non-human primates, and mouse, in coordination and collaboration with other BRAIN Initiative Cell Atlas Network (BICAN) projects. In particular, the Specialized Collaboratories are expected to complement the Comprehensive Centers in BICAN with distinct capabilities, competencies, and research aims. The overarching goal of the BICAN is to build reference brain cell atlases that will be widely used throughout the research community, providing a molecular and anatomical foundational framework for the study of brain function and disorders. Due November 9, 2021. Med-RA deadline to receive draft documents: October 27. Pilot and Feasibility Studies to Improve Technology Adoption and Reduce Health Disparities in Type 1 Diabetes Mellitus (R01 Clinical Trial Required) The purpose of this Funding Opportunity Announcement (FOA) is to support pilot and feasibility trials of interventions designed to improve technology adoption in individuals from underrepresented backgrounds with type 1 diabetes mellitus (T1D). Through successful execution, these pilot and feasibility trials should provide feasibility data for larger, pragmatic trials with the overarching goal of reducing health disparity in T1D through improving technology usage in individuals from minority racial and ethnic backgrounds. Due March 3, 2022. Med-RA deadline to receive draft documents: February 21. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: